Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.

PURPOSE To evaluate the natural history, validate previous observations, and identify prognostic factors in patients with unknown primary carcinoma (UPC). PATIENTS AND METHODS Nine hundred twenty-seven consecutive patients referred to the M.D. Anderson Cancer Center with a preliminary diagnosis of UPC were prospectively identified. A standardized evaluation narrowed the study population to 657 patients with UPC. All data were recorded and computerized for storage, retrieval, and analysis. The primary end point for the study was survival, which was calculated from the first day of patient registration. Survival curves were estimated using the Kaplan-Meier method and compared using the Cox-Mantel log-rank test. To identify important prognostic factors, univariate and multivariate analyses were conducted. RESULTS The demographics of the UPC patient population mirrored those of the general population of patients referred to our cancer center except for an excess of men among the UPC patients. Most patients had histologic or cytologic evidence of adenocarcinoma and had more than one organ site metastatically involved. Univariate and multivariate analyses identified numerous important prognostic factors with a significant influence on survival, including sex, number of organ sites involved, specific organ sites involved, and pathologic subtypes. CONCLUSION This study validated previously identified important prognostic factors for survival in UPC. Additional variables that had an impact on survival were identified and the complex interaction of the factors was explored. As patient numbers increase, this database will be able to provide further analyses of patient subsets and potentially relate specific clinical features to the evolving molecular and biochemical understanding of these malignancies.

[1]  R. Lenzi,et al.  The biology of unknown primary tumors. , 1993, Seminars in oncology.

[2]  R. Lenzi,et al.  Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. , 1993, European journal of cancer.

[3]  J. Abbruzzese,et al.  p53 gene mutation spectrum in human unknown primary tumors. , 1993, Anticancer research.

[4]  J. Hainsworth,et al.  Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[6]  J. Abbruzzese,et al.  Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Malkasian,et al.  Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin‐based chemotherapy , 1990, Cancer.

[8]  J. Verweij,et al.  Carcinoma of unknown primary: identification of a treatable subset? , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Hainsworth,et al.  Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. , 1989, Annals of internal medicine.

[10]  M. Friedlander,et al.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.

[11]  J. Hainsworth,et al.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. , 1988, Annals of internal medicine.

[12]  M. Burgess,et al.  Prognostic factors in metastatic carcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hainsworth,et al.  Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. , 1986, Annals of internal medicine.

[14]  F. Greco,et al.  The unrecognized extragonadal germ cell cancer syndrome. , 1981, Annals of internal medicine.

[15]  P. Rosen Axillary lymph node metastases in patients with occult noninvasive breast carcinoma , 1980, Cancer.

[16]  R. Steckel,et al.  Diagnostic persistence in working up metastatic cancer with an unknown primary site. , 1980, Radiology.

[17]  M. Viola,et al.  Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. , 1979, JAMA.

[18]  H. Latourette,et al.  Cervical lymph node metastases from an unknown primary. , 1979, International journal of radiation oncology, biology, physics.

[19]  R. Wilson,et al.  In pursuit of the unknown primary. , 1978, American journal of surgery.

[20]  R. M. Wolf,et al.  Metastatic and histologic presentations in unknown primary cancer. , 1977, Seminars in oncology.

[21]  J. Urban,et al.  Breast Cancer Presenting as an Axillary Mass , 1976, Annals of surgery.

[22]  R. G. Richardson,et al.  Metastases from undetected primary cancers. Clinical experience at a radiation oncology center. , 1975, The Western journal of medicine.

[23]  E. Copeland,et al.  Axillary Metastases from Unknown Primary Sites , 1973, Annals of surgery.

[24]  F. Holmes,et al.  Metastatic cancer of unknown primary site , 1970, Cancer.

[25]  D. Cox Regression Models and Life-Tables , 1972 .

[26]  P. E. Smith,et al.  Metastatic cancer without a detectable primary site. , 1967, American journal of surgery.

[27]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .